Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma

Journal of Experimental and Clinical Medicine

Volumn 2, Issue 3, 2010, Pages 93-103

  Whang Peng, Jacqueline ^a   Cheng, Ann Lii ^b   Hsu, Chiun ^b   Chen, Chien Ming ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bevacizumab (Avastin); Chemoembolization (TACE); Erlotinib (Tarceva, OS1774); Gefitinib (Iressa); Hepatocellular carcinoma (HCC); Percutaneous injection; Radiofrequency ablation; Traditional Chinese medicine; Transcatheter arterial; Vascular endothelial growth factor (VEGF)

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BELINOSTAT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUTAMIDE; FOLINIC ACID; GEMCITABINE; IODINATED POPPYSEED OIL; IODINE 131; MEGESTROL ACETATE; MENADIONE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; RHENIUM 188; SORAFENIB; THALIDOMIDE; UNINDEXED DRUG; YTTRIUM 90;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CHINESE MEDICINE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTINUOUS INFUSION; DESQUAMATION; DETOXIFICATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GENE EXPRESSION; GEOGRAPHIC DISTRIBUTION; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL HEPATECTOMY; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOMNOLENCE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77953894340     PISSN: 18783317     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1878-3317(10)60016-2     Document Type: Review

References (59)

1. El-Serag HB, Rudolph KL Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 2010, 31:55-61.
4. Ratych RE, Smith GW Anatomy of the liver. Shackelford's Surgery of the Alimentary Tract 2002, Volume 3:293-302. WB Saunders, Philadelphia. 5th ed. G.D. Zuidema, C.J. Yeo (Eds.).
5. Kao JH, Chen DS Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 2005, 25:696-703.
6. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
7. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
8. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
9. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001, 34:529-534.
10. AJCC Staging Manual 2009, Springer, New York. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene (Eds.).
11. Llovet JM, Brú C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
12. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
13. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
14. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Metroticket Investigator Study Group, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
15. Poon RT, Fan ST Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004, 10:S39-S45.
16. Pawlik TM, Esnaola NF, Vauthey JN Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl 2004, 10:S74-S80.
17. Poon RT, Fan ST, Tsang FH, Wong J Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002, 235:466-486.
18. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008, 38:37-51.
19. Llovet JM, Bruix J Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
20. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, Chen PJ, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005, 242:36-42.
21. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
22. Yen Y, Hsu C, Cheng AL, Arvelakis A, Saif MW, Emre S Hepato-cellular cancer. Emerging Cancer Therapeutics: Gastrointestinal Malignancies 2010, 93-116. Demos Medical, New York. M.W. Saif (Ed.).
23. Whang-Peng J, Chao Y Clinical trials of HCC in Taiwan. Hepatogastroenterology 1998, 45:1937-1943.
24. Yeh CN, Chen MF, Lee WC, Jeng LB Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol 2002, 81:195-202.
25. Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience. Surgery 2010, 147:676-685.
26. Chen LT, Chen MF, Lee LA, Lee PH, Jeng LB, Lin DY, Wu CC, et al. Randomized phase III study of adjuvant interferon alfa-2b in hepatocellular carcinoma with curative resection-the Taiwan Cooperative Oncology Group (TCOG T1297) study. Hepatology 2005, 42(Suppl 1):237A. [Abstract].
27. 90Y microspheres. Nucl Med Commun 2007, 28:21-24.
28. Shen YC, Hsu C, Cheng AL Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncol 2007, 2:199-210.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
30. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
31. Hsu C, Shen YC, Cheng AL Sorafenib for the treatment of hepa-tocellular carcinoma across geographic regions. Expert Rev Clin Pharmacol 2009, 2:129-136.
32. Zhu AX Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008, 112:250-259.
33. Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. In: Proceedings of the 14th European Cancer Conference of the European Cancer Organisation (ECCO), September 23-27, 2007, Barcelona, Spain. Abstract 3500.
34. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898-1903.
35. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, Artru P, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112:2733-2739.
36. Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M, Faust T, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007, 25(No. 18S (June 20 Suppl):4574.
37. O'Neil BH, Bernard SA, Goldberg RM, Moore DT, Garcia R, Marroquin C, Morse MA, et al. Phase II study of oxaliplatin, capecit-abine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008, 26(May 20 Suppl; Abstract 4604).
38. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109:1384-1390.
39. Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007, 97:862-867.
40. Hanahan D, Bergers G, Bergsland E Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
41. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010, 102:981-986.
42. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, et al. Phase II study of combining sorafenib with metronomic tegafur/ uracil for advanced hepatocellular carcinoma. J Hepatol 2010 Mar 30, [Epub ahead of print].
43. Hsu C, Lin ZZ, Lee KT, Yeh KH, Hsiao CH, Shen YC, Chang DY, et al. A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): final report. J Clin Oncol 2009, 27(May 20 Suppl; Abstract e15533).
44. Kerbel R, Folkman J Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-741.
45. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
46. Somers GF Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother 1960, 15:111-116.
47. McBride WG Thalidomide and congenital abnormalities. Lancet 1961, ii:1358.
48. D'Amato RJ, Loughnan MS, Flynn E, Folkman J Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
49. Kenyon BM, Browne F, D'Amato R Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997, 64:971-978.
50. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003, 65:242-249.
51. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, Abbruzzese JL, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005, 103:749-755.
52. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005, 103:119-125.
53. Chiou HE, Wang TE, Wang YY, Liu HW Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol 2006, 12:6955-6960.
54. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepa-tocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 2004, 183:713-719.
55. Hsu C, Chen CN, Chen LT, Wu CY, Hsieh FJ, Cheng AL Effect of thalidomide in hepatocellular carcinoma: assessment with power Doppler US and analysis of circulating angiogenic factors. Radiology 2005, 235:509-516.
56. Kaseb AO, Iwasaki M, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, Thomas MB Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009, 27(May 20 Suppl; Abstract 4522).
57. Hsu CH, Kang Y, Yang T, Su W, Sandoval-Tan J, Chiou T, Jin K, et al. A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepa-tocellular carcinoma (HCC): an interim safety report. J Clin Oncol 2009, 27(May 20 Suppl; Abstract 4585).
58. Delman KA, Brown TD, Thomas M, et al. Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepa-tocellular carcinoma. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(No. 16S (June 1 Suppl)):4139.
59. Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res 2009, 29:4083-4092.